apocell Home Contact Us

ApoCell Biomarker Test Menu


Quantitative Immunofluorescent and Immunohistochemistry Targets

  • Protein detection in tissue specimens, PBMCs, CTCs, rare cell subsets, BMAs, FNAs.
  • Data from high content quantitative image analysis reported as mean fluorescence intensity (MFI) and/or percentage positive on a cell population or per cell basis.
  • IHC reporting available as H-Score.
Immunofluorescent/Immunohistochemistry Targets
ABCG2 ACPP AKT ALDH1
ALDH1A1 ALK1 AR AR-v7
Axin2 AXL β-catenin B7-H4
B12 BMP-9 BMP-10 BubR1
CA19-9 Calreticulin CD3 CD4
CD14 CD15 CD19 CD24
CD31 CD32 CD34 CD41
CD44 CD45 CD45RO CD47
CD56 CD68/SR-D1 CD86 (B7-2) CD87
CD90 CD105 CD123 CD133
CD142 CD146 CD163 CD172a
CD184 CD206 CD303 CEA
Claudin-18 Coagulation Factor III CXCR4 Cytokeratin
Detyrosinated α Tubulin E-Cadherin EGFR EpCAM
ErbB2/HER2 ERG ERK FGFR1
FRS2 γ-H2AX GDF5 Glutubulin
ID1 iNOS Ki67 KLH
LC3 MAPK/p44/42 MUC16/CA-125 MUC1/CD227
N-Cadherin p63 pAKT pEGFR
pERK pFAK pFRS2 pErbB2/pHER2 (Tyr1221/1222)
pSMAD5 Pan-CK Plectin PSMA
PTEN RAD51 Ran SMAD5
Snail Stathmin 1 Syndecan-1/CD138 TCL1
TF Topo 1 Topo 2 TTF-1
TUNEL TWIST Uroplakin 1b VEGFR2/CD309
Vimentin WNT2

* Additional markers are available upon request.


CTC Profiling

  • Phenotypes detected in CTCs enriched from whole blood.
  • Data from high content quantitative image analysis reported as total counts on a per mL basis.
  • Proprietary panels consisting of multiple phenotypes based on internal data. All disease indications are Stage IV, unless otherwise indicated.
Quantitative Immunofluorescent Phenotype Panels
Disease Cancer Specific Markers Panel
Advanced Solid Tumor Phase I Epithelial
Epithelial/Mesenchymal Transition
Blastic Plasmacytoid Dendritic Cell Neoplasm Leukemic Stem Cells
Bladder Cancer Epithelial
Epithelial/Mesenchymal Transition
Stem Cells (Stage I-III)
Breast Cancer EGFR Epithelial
Epithelial/Mesenchymal Transition
Stem Cells (Stage I-III)
Head and Neck Squamous Cell Carcinoma Epithelial
Epithelial/Mesenchymal Transition
Non-Small Cell Lung Cancer TTF-1 Epithelial
Epithelial/Mesenchymal Transition
Ovarian Cancer CA-125 Epithelial
Epithelial/Mesenchymal Transition
Pancreatic Cancer Epithelial
Epithelial/Mesenchymal Transition
Stem Cells (Stage III)
Prostate Cancer PSMA, PAP Epithelial
Epithelial/Mesenchymal Transition
Renal Cell Carcinoma CA-125 Epithelial
Epithelial/Mesenchymal Transition
Small Cell Lung Cancer CD56, TTF-1 Epithelial
Epithelial/Mesenchymal Transition
Stem Cells
Triple Negative Breast Cancer Epithelial
Epithelial/Mesenchymal Transition

* Additional markers and custom immunofluorescence panels are available upon request.


Flow Cytometry Targets

  • Protein detection in whole blood, bone marrow aspirates (BMA), and rare cell subsets.
  • Data reported as mean fluorescence intensity (MFI) and/or percentage positive cells.
Flow Cytometry Targets
ανβ3 ανβ5 Calreticulin CCR3
CD19 CD36 CD40 CD47
CD63 CD68 CD71 CD138
CD235a FoxP3 pCSF-1R pPDGFRβ
pTIE2 pVEGFR PAR PARP
PD1 PDGFRβ PDL1 PDL2
SIRPα TIE2 VEGFR

* Additional markers are available upon request.


Flow Cytometry Panels

  • Protein detection in whole blood, bone marrow aspirates (BMA), and rare cell subsets.
  • Data reported as total counts and/or percentage positive cells.
Flow Cytometry Panels
Circulating Endothelial Cells (CECs)
Circulating Endothelial Progenitors (CEPs)
Erythroid Progenitor Cells
Macrophages
Myeloid Cells
Natural Killer (NK) Cells
Reticulocytes
Stem Cells (Hematopoetic and Leukocyte)
T Cells: Tc, Th, Tmem, Treg

* Additional markers and custom flow cytometry panels are available upon request.


Cytogenetics and Fluorescent in situ Hybridization (FISH)

  • DNA abnormality detection in tissue specimens, whole blood, rare cell subsets, BMA.
  • Data reported as deletion, amplification, or translocation.
Cytogenetic Targets
AR cKit CK2α cMET
EGFR EML4-ALK FGFR1 G-Banding
HER2 IGF1R Notch3 PTEN
ROS-1 TMPRSS-ERG Topo I Topo II
Urovysion VHL

* Additional FISH probe targets are available upon request.


Molecular Testing

  • Gene expression and mutation detection (targeted sequencing and NGS) in tissue specimens, whole blood, and rare cell subsets.
  • Detection platforms using digital PCR, RT-PCR, and mass spectrometry.
Gene Expression Targets Gene Mutation Targets
ALDH1A1 AR AR-v1 BRAF KRAS
AR-v7 AR-v567es Axin2 EGFR (T790M, L858R, E746_A750)
β-catenin CD133 CK20
ETV1 FRA Hes6
Hey1 MAGED2 MIA
MLANA Mesothelin PKN3
PRMT2 PTEN SERPINE2
SOX2 Survivin

Mutations Conferring Resistance to ALK TKI Therapy
Mutation Location Within the Kinase Domain ALK Fusion
ALK 1151Tins N terminal to the Cα helix Not reported
ALK L1152R N terminal to the Cα helix EML4-ALK E6;A20
ALK C1156Y N terminal to the Cα helix EML4-ALK E13;A20
ALK F1174La C terminal to the Cα helix RANBP2-ALK
ALK L1196M Gatekeeper mutation EML4-ALK E13;A20
EML4-ALK E13;A20 (x1)
EML4-ALK E6;A20 (x1)
ALK L1198Fb ATP binding pocket Not reported
ALK G1202R Solvent front Not reported
ALK S1206Y Solvent front Not reported
ALK G1269A ATP binding pocket EML4-ALK E6;A19 (x1)
EML4-ALK E6;A20 (x1)
EML4-ALK E13;A20 (x2)
EGFR L858R EGFR Activating N/A

Digital PCR Target Mutations
Gene Protein Variant Nucleotide Variant
ALK p.R1275Q c.3824G>A
BRAF p.V600E c.1799T>A
c.1799-1800delTGinsAA
EGFR p.L858R c.2573T>G
p.T790M c.2369C>T
p.E746-A750del c.2235del15
FLT3 p.D835Y c.2503G>T
GNAS p.R201C c.601C>T
p.R201H c.602G>A
HER2 p.L755S c.2264T>C
IDH1 p.R132H c.395G>A
p.R132L c.395G>T
p.R132S c.394C>A
p.R132G c.394C>G
IDH2 p.R140Q c.419G>A
p.R172K c.515G>A
JAK2 p.V617F c.1849G>T
KIT p.D816V c.2447A>T
KRAS p.G12C c.34G>T
p.G12D c.35G>A
p.G12S c.34G>A
p.G12V c.35G>T
p.G12A c.35G>C
p.C12R c.34G>C
p.G13D c.38G>A
PIK3CA p.H1047R c.3140A>G
p.E545K c.1633G>A
TP53 p.R273H c.818G>A

* Additional molecular markers and commercially available custom-designed NGS panels are available upon request